** Medical device maker GeneDx's shares WGS.O surge 19.3% to $91.1 premarket
** Co posts Q4 revenue of $95.3 mln, beating analyst est of $82.23 mln as per data compiled by LSEG
** Co forecasts 2025 revenue in the range of $350 mln to $360 mln, higher than analysts' expectations of $338.8 mln
** WGS makes medical devices used to diagnose rare genetic disorders, epilepsy and autism
** Co reports adj Q4 net income of $16.8 mln vs analyst est of $2.9 mln
** Stock had risen 17.3x in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。